BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348-65. [PMID: 29431871 DOI: 10.1111/cei.13112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Edwards CJ, Monnet J, Ullmann M, Vlachos P, Chyrok V, Ghori V. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol 2019;38:3381-90. [DOI: 10.1007/s10067-019-04679-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
2 Zhang H, Wang H, Wei H, Chen H, Liu J, Li C, Zhu X, Li X, Yu J, Zhou Y, Yang X, Wang Z, Wu M, Ding Y. A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men. Front Pharmacol 2020;11:609522. [PMID: 33569002 DOI: 10.3389/fphar.2020.609522] [Reference Citation Analysis]
3 Cai L, Li L, Cheng H, Ding Y, Biao Z, Zhang S, Geng S, Liu Q, Fang H, Song Z, Lu Y, Li S, Guo Q, Tao J, He L, Gu J, Yang Q, Han X, Gao X, Deng D, Li S, Wang Q, Zhu J, Zhang J. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther 2022;39:583-97. [PMID: 34816373 DOI: 10.1007/s12325-021-01899-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 von Bremen H, Gamboa LM, Zernicke J, Poddubnyy D, Feist E. Evaluation von Immunoassays zum Nachweis von Anti-Drug Antikörpern gegen Infliximab und korrespondierenden Infliximab Serumspiegeln bei Spondyloarthritis im klinischen Alltag. Aktuelle Rheumatologie 2021;46:465-73. [DOI: 10.1055/a-1033-8153] [Reference Citation Analysis]
5 Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ, Krasenbaum LJ, Shen H, Stratton J. Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain 2021;22:3. [PMID: 33413094 DOI: 10.1186/s10194-020-01211-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
6 Doshi S, Wang H, Chow V. Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK Modeling. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2021.11.016] [Reference Citation Analysis]
7 Maselis K, Žekevičiūtė R, Vaitkus A. Refractoriness to drugs in migraine may be the result of developing anti-drug antibodies. Med Hypotheses 2021;146:110459. [PMID: 33360448 DOI: 10.1016/j.mehy.2020.110459] [Reference Citation Analysis]
8 Guan L, Crasta KC, Maier AB. Assessment of cell cycle regulators in human peripheral blood cells as markers of cellular senescence. Ageing Res Rev 2022;78:101634. [PMID: 35460888 DOI: 10.1016/j.arr.2022.101634] [Reference Citation Analysis]
9 Lu S, Bowsher RR, Clancy A, Rosen A, Zhang M, Yang Y, Koeck K, Gao M, Potocka E, Guo W, Jen KY, Im E, Milton A. An Integrated Analysis of Dostarlimab Immunogenicity. AAPS J 2021;23:96. [PMID: 34324079 DOI: 10.1208/s12248-021-00624-7] [Reference Citation Analysis]
10 Beeg M, Burti C, Allocati E, Ciafardini C, Banzi R, Nobili A, Caprioli F, Garattini S, Gobbi M. Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera. Sci Rep 2021;11:14976. [PMID: 34294782 DOI: 10.1038/s41598-021-94431-x] [Reference Citation Analysis]
11 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
12 Gorovits B. Current Considerations for Immunoglobulin Isotype Characterization of Antibody Response against Biotherapeutics. AAPS J 2020;22:144. [PMID: 33161459 DOI: 10.1208/s12248-020-00530-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 West TA, Sam M, Toong C. Comparison of three commercially available ELISA assays for anti-infliximab antibodies. Pathology 2021;53:508-14. [PMID: 33272693 DOI: 10.1016/j.pathol.2020.08.020] [Reference Citation Analysis]
14 Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgo A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, Sarzi-puttini P, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Autoimmunity Reviews 2020;19:102509. [DOI: 10.1016/j.autrev.2020.102509] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kim H, Alten R, Cummings F, Danese S, D'Haens G, Emery P, Ghosh S, Gilletta de Saint Joseph C, Lee J, Lindsay JO, Nikiphorou E, Parker B, Schreiber S, Simoens S, Westhovens R, Jeong JH, Peyrin-Biroulet L. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 2021;13:1868078. [PMID: 33557682 DOI: 10.1080/19420862.2020.1868078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Strand V, Gonçalves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. BioDrugs 2020;34:27-37. [PMID: 31721107 DOI: 10.1007/s40259-019-00394-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
17 El-hussuna A, Myrelid P, Holubar SD, Kotze PG, Mackenzie G, Pellino G, Winter D, Davies J, Negoi I, Grewal P, Gallo G, Sahnan K, Rubio-perez I, Clerc D, Demartines N, Glasbey J, Regueiro M, Sherif AE, Neary P, Pata F, Silverberg M, Clermont S, Chadi SA, Emile S, Buchs N, Millan M, Minaya-bravo A, Elfeki H, De Simone V, Shalaby M, Gutierrez C, Ozen C, Yalçınkaya A, Rivadeneira D, Sturiale A, Yassin N, Spinelli A, Warusavitarne J, Ioannidis A, Wexner S, Mayol J; Open Source Research Collaborating Group (#OpenSourceResearch). Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. Crohn's & Colitis 360 2019;1:otz021. [DOI: 10.1093/crocol/otz021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol 2020;182:316-26. [PMID: 31206593 DOI: 10.1111/bjd.18220] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
19 Pan X, Stader F, Abduljalil K, Gill KL, Johnson TN, Gardner I, Jamei M. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. AAPS J 2020;22. [DOI: 10.1208/s12248-020-00460-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
20 Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 2021;17:81-97. [PMID: 33318665 DOI: 10.1038/s41584-020-00540-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Li Y, Mai Y, Cao P, Wen X, Fan T, Wang X, Ruan G, Tang S, Ding C, Zhu Z. Relative Efficacy and Safety of Anti-Inflammatory Biologic Agents for Osteoarthritis: A Conventional and Network Meta-Analysis. JCM 2022;11:3958. [DOI: 10.3390/jcm11143958] [Reference Citation Analysis]
22 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Akpalu DE, Frederick B, Nnane IP, Yao Z, Shen F, Ort T, Fink D, Dogmanits S, Raible D, Sharma A, Xu Z. Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects. J Clin Pharmacol 2019;59:968-78. [PMID: 30776134 DOI: 10.1002/jcph.1393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
24 Hoshitsuki K, Rathod S, Ramsey MJ, Zhu L, Moreland LW, Fernandez CA. Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. J Pharmacol Exp Ther 2020;375:488-97. [PMID: 33008870 DOI: 10.1124/jpet.120.000179] [Reference Citation Analysis]
25 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
26 Gorovits B, Peng K, Kromminga A. Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics. BioDrugs 2020;34:39-54. [DOI: 10.1007/s40259-019-00389-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
27 Li M, Zhou X. Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis. Inflammopharmacology 2021;29:1371-8. [PMID: 34406596 DOI: 10.1007/s10787-021-00854-3] [Reference Citation Analysis]
28 Heron CE, Ghamrawi RI, Balogh EA, Feldman SR. Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection. Am J Clin Dermatol 2021;22:221-31. [PMID: 33169802 DOI: 10.1007/s40257-020-00569-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, Scharl M. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflamm Intest Dis 2021;6:38-47. [PMID: 33850838 DOI: 10.1159/000511296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Vogelzang EH, Loeff FC, Derksen NIL, Kruithof S, Ooijevaar-de Heer P, van Mierlo G, Linty F, Mok JY, van Esch W, de Bruin S, Vlaar APJ, Seppen B, Leeuw M, van Oudheusden AJG, Buiting AGM, Jim KK, Vrielink H, Swaneveld F, Vidarsson G, van der Schoot CE, Wever PC, Li W, van Kuppeveld F, Murk JL, Bosch BJ, Wolbink GJ, Rispens T; Amsterdam University Medical Center COVID-19 Biobank Study Group,. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19. J Immunol 2020;205:3491-9. [PMID: 33127820 DOI: 10.4049/jimmunol.2000767] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
31 Lodhia N, Rao S. Updates in therapeutic drug monitoring in inflammatory bowel disease. World J Gastroenterol 2022; 28(21): 2282-2290 [DOI: 10.3748/wjg.v28.i21.2282] [Reference Citation Analysis]
32 Furihata K, Ishiguro Y, Yoshimura N, Ito H, Katsushima S, Kaneko E, Shimabe M, Mukai M, Watanabe R, Morishige T. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis. Clin Pharmacol Drug Dev 2021;10:870-83. [PMID: 33512065 DOI: 10.1002/cpdd.918] [Reference Citation Analysis]
33 Ding X, Zhu R, Wu J, Xue L, Gu M, Miao L. Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients. Clin Transl Sci 2020;13:547-54. [PMID: 31961477 DOI: 10.1111/cts.12738] [Reference Citation Analysis]
34 Gimeno-Gracia M, Gargallo-Puyuelo CJ, Gomollón F. Bioequivalence studies with anti-TNF biosimilars. Expert Opin Biol Ther 2019;19:1031-43. [PMID: 30574813 DOI: 10.1080/14712598.2019.1561851] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Sánchez-Hernández JG, Pérez-Blanco JS, Rebollo N, Muñoz F, Prieto V, Calvo MV. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease. Eur J Pharm Sci 2020;150:105369. [PMID: 32416256 DOI: 10.1016/j.ejps.2020.105369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Sensi M, Berto M, Gentile S, Pinti M, Conti A, Pellacani G, Salvarani C, Cossarizza A, Bortolotti CA, Biscarini F. Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. Chem Commun (Camb) 2021;57:367-70. [PMID: 33325465 DOI: 10.1039/d0cc03399e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
37 Yonemura T, Yazawa R, Haranaka M, Kawakami K, Takanuma M, Kanzo T, Stefanidis D, Arai Y. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants. BMC Pharmacol Toxicol 2022;23:6. [PMID: 34998419 DOI: 10.1186/s40360-021-00545-3] [Reference Citation Analysis]
38 Gunzinger J, Moore P, Athimalaipet R, Dick A. Adalimumab in the treatment of pediatric patients with chronic noninfectious anterior uveitis. Expert Review of Ophthalmology 2021;16:231-41. [DOI: 10.1080/17469899.2021.1935240] [Reference Citation Analysis]